SCHEMBL25247673

SCHEMBL25247673

N#CN1C[C@H](NC(=O)c2ncc(-c3cccc(C(F)(F)F)c3)o2)C[C@H]1Cn1cccn1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 5/20 0.46
▸ HDAC6 Q9UBN7 5/20 0.46
▸ USP30 Q70CQ3 1/20 0.38
▸ GRIN2B Q13224 6/20 0.36
▸ GRIN1 Q05586 5/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ KCNH2 Q12809 1/20 0.36
▸ F2R P25116 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ PIM1 P11309 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ RORC P51449 1/20 0.34
▸ ACKR3 P25106 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24073263 0.91 HDAC1 (0.46) HDAC1HDAC6USP30GRIN2BGRIN1
SCHEMBL25260376 0.91 HDAC1 (0.46) HDAC1HDAC6USP30GRIN2BGRIN1
SCHEMBL30370531 0.91 HDAC1 (0.46) HDAC1HDAC6USP30GRIN2BGRIN1
SCHEMBL25248106 0.89 USP30 (0.37) HDAC1HDAC6USP30PIM1
SCHEMBL25215099 0.89 FAAH (0.43) HDAC1HDAC6USP30
SCHEMBL29268945 0.88 HDAC1 (0.47) HDAC1HDAC6GRIN2BGRIN1CYP2C9
SCHEMBL29268951 0.88 HDAC1 (0.47) HDAC1HDAC6GRIN2BGRIN1CYP2C9
SCHEMBL25248803 0.88 HDAC1 (0.47) HDAC1HDAC6GRIN2BGRIN1CYP2C9
SCHEMBL25215189 0.86 UCHL1 (0.37) USP30CYP2C9CYP2C19KCNH2F2R
SCHEMBL24073643 0.86 HDAC1 (0.48) HDAC1HDAC6USP30GRIN2BGRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250034122-A1 SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2025-01-30 — — US disclosed
EP-4441044-A1 SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS Mission Therapeutics Limited (GB) 2024-10-09 — — EP disclosed
CN-118302422-A Substituted N-cyanopyrrolidines having activity as USP30 inhibitors 特殊治疗有限公司 2024-07-05 — — CN disclosed
WO-2023099561-A1 SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2023-06-08 — — WO disclosed
WO-2023099561-A1 SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2023-06-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250034122-A1 SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS USP30, USP47, USP1 HDAC1 560/4885HDAC6 764/4885USP30 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback